MCID: ESP027
MIFTS: 36

Esophagus Squamous Cell Carcinoma malady

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Esophagus Squamous Cell Carcinoma

Aliases & Descriptions for Esophagus Squamous Cell Carcinoma:

Name: Esophagus Squamous Cell Carcinoma 12 14
Squamous Cell Carcinoma of Esophagus 12 69
Esophageal Squamous Cell Carcinoma 42
Scc of Esophagus 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3748
MeSH 42 C562729
NCIt 47 C4024
SNOMED-CT 64 276804009
UMLS 69 C0279626

Summaries for Esophagus Squamous Cell Carcinoma

Disease Ontology : 12 An esophageal carcinoma that derives from epithelial squamous cells located in the esophagus.

MalaCards based summary : Esophagus Squamous Cell Carcinoma, also known as squamous cell carcinoma of esophagus, is related to esophageal cancer and squamous cell carcinoma, and has symptoms including chest pain, nausea and vomiting and feeding difficulties in infancy. An important gene associated with Esophagus Squamous Cell Carcinoma is DSE (Dermatan Sulfate Epimerase), and among its related pathways/superpathways are Apoptotic cleavage of cellular proteins and Dendritic Cells Developmental Lineage Pathway. The drugs Capecitabine and Irinotecan have been mentioned in the context of this disorder. Affiliated tissues include lymph node and the esophagus, and related phenotype is no phenotypic analysis.

Related Diseases for Esophagus Squamous Cell Carcinoma

Graphical network of the top 20 diseases related to Esophagus Squamous Cell Carcinoma:



Diseases related to Esophagus Squamous Cell Carcinoma

Symptoms & Phenotypes for Esophagus Squamous Cell Carcinoma

Human phenotypes related to Esophagus Squamous Cell Carcinoma:

32 (show all 8)
id Description HPO Frequency HPO Source Accession
1 chest pain 32 HP:0100749
2 nausea and vomiting 32 HP:0002017
3 feeding difficulties in infancy 32 HP:0008872
4 abnormality of the voice 32 HP:0001608
5 cough 32 HP:0012735
6 lymphadenopathy 32 HP:0002716
7 clinodactyly of the 5th toe 32 HP:0001864
8 esophageal carcinoma 32 HP:0011459

MGI Mouse Phenotypes related to Esophagus Squamous Cell Carcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 no phenotypic analysis MP:0003012 8.92 CDH1 RUNX3 SART1 WWOX

Drugs & Therapeutics for Esophagus Squamous Cell Carcinoma

Drugs for Esophagus Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 164)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Capecitabine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 154361-50-9 60953
2
Irinotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
3
Camptothecin Experimental Phase 4,Phase 3,Phase 2,Phase 1 7689-03-4
4 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
5 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
6 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1
7 topoisomerase I inhibitors Phase 4,Phase 3,Phase 2,Phase 1
8 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
9
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
10
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
11
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
12
Cetuximab Approved Phase 2, Phase 3, Phase 1 205923-56-4 56842117 2333
13
Oxaliplatin Approved, Investigational Phase 2, Phase 3, Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
14
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
15
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
16
Levoleucovorin Approved Phase 2, Phase 3,Phase 1 68538-85-2
17
Gefitinib Approved, Investigational Phase 3,Phase 2,Phase 1 184475-35-2 123631
18
Nedaplatin Approved Phase 3,Phase 2,Phase 1 95734-82-0
19
Pembrolizumab Approved Phase 3,Phase 2 1374853-91-4
20
Vinblastine Approved Phase 3 865-21-4 13342 241903
21
Vinorelbine Approved, Investigational Phase 3,Phase 2 71486-22-1 60780 44424639
22
Megestrol acetate Approved, Vet_approved Phase 3 595-33-5 11683
23
Trioxsalen Approved Phase 3 3902-71-4 5585
24
nivolumab Approved Phase 3 946414-94-4
25
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
26
leucovorin Approved, Nutraceutical Phase 2, Phase 3, Phase 1 58-05-9 54575, 6560146 143
27
Docetaxel Approved May 1996, Investigational Phase 3,Phase 1,Phase 2 114977-28-5 148124 9877265
28
Caffeic acid Experimental Phase 3 331-39-5 1549111
29 Analgesics Phase 3,Phase 2
30 Analgesics, Non-Narcotic Phase 3,Phase 2
31 Anti-Inflammatory Agents Phase 3,Phase 2,Phase 1
32 Anti-Inflammatory Agents, Non-Steroidal Phase 3,Phase 2
33 Antipyretics Phase 3
34 Antirheumatic Agents Phase 3,Phase 2
35 Cyclooxygenase Inhibitors Phase 3,Phase 2
36 Fibrinolytic Agents Phase 3
37 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
38 Platelet Aggregation Inhibitors Phase 3
39 Antimitotic Agents Phase 3,Phase 2,Phase 1
40
s 1 (combination) Phase 3,Phase 2
41 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
42 Vitamin B Complex Phase 2, Phase 3
43 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
44
Cobalt Phase 3,Phase 2 7440-48-4 104729
45 Pharmaceutical Solutions Phase 3
46 Antidotes Phase 2, Phase 3,Phase 1
47 Hematinics Phase 2, Phase 3
48 Micronutrients Phase 2, Phase 3
49 Protective Agents Phase 2, Phase 3, Phase 1
50 Trace Elements Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 247)
id Name Status NCT ID Phase
1 Phase II Trial Evaluating Irinotecan and Capecitabine Relapsed/Refractory Upper GI Tumours Completed NCT00220168 Phase 4
2 Chemoradiation With or Without Nimotuzumab in Treating Esophageal Cancer Patients Who Suffer With Recurrence in Regional Lymph Nodes After Esophagectomy Unknown status NCT01402180 Phase 2, Phase 3
3 Chemoprevention of Esophageal Squamous Cell Carcinoma (ESCC) With Aspirin and Tea Polyphenols Unknown status NCT01496521 Phase 3
4 Elective or Prophylactic Nodal Irradiation for Esophageal Cancer Unknown status NCT01551589 Phase 3
5 Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Cancer: ESWN 01 Trial Unknown status NCT02319187 Phase 3
6 Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus Unknown status NCT00002884 Phase 3
7 Cisplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients With Esophageal Cancer Unknown status NCT00509561 Phase 2, Phase 3
8 Surgery With or Without Chemotherapy in Treating Patients With Stage II or Stage III Cancer of the Esophagus Completed NCT00002897 Phase 3
9 Surgery or Chemoradiation for Esophageal Cancer Completed NCT01032967 Phase 3
10 Surgery With or Without Radiation Therapy and Chemotherapy in Treating Patients With Esophageal Cancer Completed NCT00047112 Phase 3
11 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Cancer of the Esophagus Completed NCT00002631 Phase 3
12 Surgery With or Without Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus Completed NCT00003118 Phase 3
13 Radiation Therapy + Combination Chemotherapy as 1st-Line Therapy for Patients With Inoperable Esophageal Cancer Completed NCT00861094 Phase 2, Phase 3
14 Gefitinib in Treating Patients With Esophageal Cancer That is Progressing After Chemotherapy Completed NCT01243398 Phase 3
15 Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal Squamous Cell Carcinoma Recruiting NCT02677597 Phase 3
16 Chemoradiotherapy With or Without Enteral Nutrition Intervention for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma Recruiting NCT02399306 Phase 3
17 Role of Esophagectomy in Complete Responders to CCRT Recruiting NCT01740375 Phase 3
18 Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma Recruiting NCT02611700 Phase 3
19 A Comparison of Paclitaxel-based Three Regimens Concurrent With Radiotherapy for Patients With Local Advanced Esophageal Cancer Recruiting NCT02459457 Phase 3
20 A Phase III Trail of Adjuvant Chemoradiotherapy Versus Adjuvant Radiotherapy in Esophageal Squamous Cell Carcinoma Recruiting NCT02570893 Phase 3
21 Neoadjuvant Chemotherapy Versus Surgery Alone for Esophageal Squamous Cell Carcinoma Recruiting NCT02395705 Phase 3
22 A Phase III Study of Nimotuzumab Plus Concurrent Chemoradiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma Recruiting NCT02409186 Phase 3
23 Is ENI Necessary For Patients With Thoracic Esophageal Cancer After Esophagectomy And With Pathological Stage Of T1-2,N+,M0 Recruiting NCT01398449 Phase 3
24 Different Cycles of Cisplatin-5-fluorouracil for the Chemoradiotherapy of Esophageal Squamous Cancer Recruiting NCT02607540 Phase 3
25 Chemoradiotherapy of Capecitabine With or Without Oxaliplatin Versus Cisplatin-5-FU for Esophageal Squamous Cancer Recruiting NCT02025036 Phase 3
26 Adjuvant Chemotherapy With Paclitaxel and Cisplatin in Lymph Node-Positive Adjuvant Chemotherapy in the Treatment of the Lymph Node Positive Thoracic Esophageal Squamous Cell Carcinoma Recruiting NCT02461043 Phase 3
27 Improve the Treatment of Thoracic Esophageal Cancer Recruiting NCT01137123 Phase 3
28 Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181) Recruiting NCT02564263 Phase 3
29 The Role of Different Cycles of Chemotherapy(Capecitabine-oxaliplatin) in Esophageal Chemoradiotherapy Recruiting NCT02604615 Phase 3
30 Efficacy of Intensity Modulated Radiation Therapy After Surgery in Early Stage of Esophageal Carcinoma; Recruiting NCT01745107 Phase 3
31 Study of Docetaxel or Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Esophageal Cancer Recruiting NCT02465736 Phase 3
32 Adjuvant Therapies or Surgery Alone for High Risk pN0 Esophageal Cancer Recruiting NCT02891083 Phase 3
33 Different Cycles of Capecitabine Usage in Esophageal Cancer Concurrent Chemoradiotherapy Recruiting NCT02603159 Phase 3
34 S-1 Concurrent With Radiotherapy Versus Radiotherapy for Elderly Patients With Esophageal Cancer Recruiting NCT02813967 Phase 3
35 Effect of Megestrol Acetate on the Quality of Life of Patients With Esophageal Carcinoma Recruiting NCT02644408 Phase 3
36 Study of SHR-1210 Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal Cancer Recruiting NCT03099382 Phase 3
37 Simultaneous Modulated Accelerated Boost Versus Standard Dose Radiotherapy in Esophageal Cancer Recruiting NCT02556762 Phase 3
38 Clinical Study of Time Optimizing of Endoscopic Photodynamic Therapy on Esophageal and/or Gastric Cardiac Cancer Recruiting NCT02628665 Phase 3
39 Docetaxol Plus Cisplatin Versus 5-Fu Plus Cisplatin as 1st-line Chemotherapy in Advanced ESCC Patients Recruiting NCT03002064 Phase 3
40 Comparison of Systematic Surgery Versus Surveillance and Rescue Surgery in Operable Oesophageal Cancer With a Complete Clinical Response to Radiochemotherapy Recruiting NCT02551458 Phase 2, Phase 3
41 Study of Chemoradiotherapy in Oesophageal Cancer Including PET Response and Dose Escalation Recruiting NCT02741856 Phase 2, Phase 3
42 A Phase III Study of Comparing Paclitaxel Plus 5-Fluorouracil Versus Cisplatin Plus 5-Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Carcinoma Active, not recruiting NCT01591135 Phase 3
43 Phase III Study of Neo-adjuvant Chemoradiotherapy Followed by Surgery for Squamous Cell Esophageal Cancer Active, not recruiting NCT01216527 Phase 3
44 Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery Active, not recruiting NCT01107639 Phase 3
45 Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer Active, not recruiting NCT00655876 Phase 3
46 The Efficacy and Safety of Caffeic Acid for Esophageal Cancer Enrolling by invitation NCT03070262 Phase 3
47 Comparison Between NCRT and NCT Followed by MIE for Treatment of Locally Advanced Resectable ESCC Not yet recruiting NCT03001596 Phase 3
48 Robot Assisted Thoraco-Laparoscopic Esophagectomy Versus Conventional Thoraco-Laparoscopic Esophagectomy Not yet recruiting NCT03094351 Phase 3
49 A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin Not yet recruiting NCT03143153 Phase 3
50 Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell Carcinoma Suspended NCT02272699 Phase 2, Phase 3

Search NIH Clinical Center for Esophagus Squamous Cell Carcinoma

Cochrane evidence based reviews: esophageal squamous cell carcinoma

Genetic Tests for Esophagus Squamous Cell Carcinoma

Anatomical Context for Esophagus Squamous Cell Carcinoma

MalaCards organs/tissues related to Esophagus Squamous Cell Carcinoma:

39
Lymph Node

The Foundational Model of Anatomy Ontology organs/tissues related to Esophagus Squamous Cell Carcinoma:

18
The Esophagus

Publications for Esophagus Squamous Cell Carcinoma

Articles related to Esophagus Squamous Cell Carcinoma:

(show all 12)
id Title Authors Year
1
Amplification and overexpression of CTTN and CCND1 at chromosome 11q13 in Esophagus squamous cell carcinoma (ESCC) of North Eastern Chinese Population. ( 27877079 )
2016
2
Kaempferol inhibits cell proliferation and glycolysis in esophagus squamous cell carcinoma via targeting EGFR signaling pathway. ( 26831667 )
2016
3
Pretreatment lymphopenia is an easily detectable predictive and prognostic marker in patients with metastatic esophagus squamous cell carcinoma receiving first-line chemotherapy. ( 26814381 )
2016
4
Human papillomavirus types 16 and 18 in esophagus squamous cell carcinoma: a meta-analysis. ( 23916383 )
2013
5
Notch1 is a 5-fluorouracil resistant and poor survival marker in human esophagus squamous cell carcinomas. ( 23409141 )
2013
6
Prognostic Value of Tumor-Infiltrating Mast Cells in Outcome of Patients with Esophagus Squamous Cell Carcinoma. ( 24091743 )
2013
7
Dermatan sulfate is involved in the tumorigenic properties of esophagus squamous cell carcinoma. ( 22350411 )
2012
8
Retrospective study of gemcitabine based chemotherapy for unresectable or recurrent esophagus squamous cell carcinoma refractory to first line chemotherapy. ( 23098537 )
2012
9
Prediagnostic smoking and postoperative survival in lymph node-negative esophagus squamous cell carcinoma patients. ( 22913634 )
2012
10
Analysis of the RUNX3 gene methylation in serum DNA from esophagus squamous cell carcinoma, gastric and colorectal adenocarcinoma patients. ( 22234069 )
2011
11
[Transforming growth factor beta1 regulation of epithelial-mesenchymal transition in esophagus squamous cell carcinoma]. ( 19094466 )
2008
12
Human papillomavirus DNA sequences in esophagus squamous cell carcinoma. ( 7912679 )
1994

Variations for Esophagus Squamous Cell Carcinoma

Expression for Esophagus Squamous Cell Carcinoma

Search GEO for disease gene expression data for Esophagus Squamous Cell Carcinoma.

Pathways for Esophagus Squamous Cell Carcinoma

Pathways related to Esophagus Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
11.22 CDH1 VIM
2 10.84 CDH1 RUNX3
3 9.88 CDH1 VIM

GO Terms for Esophagus Squamous Cell Carcinoma

Cellular components related to Esophagus Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 Golgi apparatus GO:0005794 8.92 CDH1 DSE SART1 WWOX

Biological processes related to Esophagus Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular matrix disassembly GO:0022617 8.62 CDH1 KLK7

Molecular functions related to Esophagus Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 glycoprotein binding GO:0001948 8.62 CDH1 VIM

Sources for Esophagus Squamous Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....